Galectin-3 levels are elevated following nintedanib treatment

• Egile Nagusiak: Gali Epstein Shochet (Egilea), Alon Pomerantz (Egilea), David Shitrit (Egilea), Becky Bardenstein-Wald (Egilea), Kjetil Ask (Egilea), Mark Surber (Egilea), Noa Rabinowicz (Egilea), Yair Levy (Egilea), Sydney Benchetrit (Egilea), Evgeny Edelstein (Egilea), Tali Zitman-Gal (Egilea)
• Formatua: Liburua
• Argitaratua: SAGE Publishing, 2020-11-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background and Aims: Idiopathic pulmonary fibrosis (IPF) is a common and severe form of pulmonary fibrosis. Nintedanib, a triple angiokinase inhibitor, is approved for treating IPF. Galectin 3 (Gal-3) activates a variety of profibrotic processes. Currently, the Gal-3 inhibitor TD139 is being tested...